Pharmagen (PHRX) Stock Overview

Distributes specialty drugs to hospitals, acute care facilities, surgery centers, and other healthcare practitioners in the United States. More details

PHRX fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	0/6
Dividends	0/6

Risk Analysis

Does not have a meaningful market cap ($517)

Latest financial reports are more than a year old

Shares are highly illiquid

PHRX Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View Stock Community

Pharmagen, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Pharmagen
Historical stock prices
Current Share Price	US$0.000001
52 Week High	US$0.0001
52 Week Low	US$0.000001
Beta	0
1 Month Change	0%
3 Month Change	0%
1 Year Change	0%
3 Year Change	0%
5 Year Change	-99.75%
Change since IPO	-100.00%

Recent News & Updates

No updates

Recent updates

No updates

Shareholder Returns

	PHRX	US Healthcare	US Market
7D	0%	0.9%	0.8%
1Y	0%	-26.2%	20.5%

Return vs Industry: PHRX exceeded the US Healthcare industry which returned -26.3% over the past year.

Return vs Market: PHRX underperformed the US Market which returned 20.8% over the past year.

Price Volatility

Is PHRX's price volatile compared to industry and market?
PHRX volatility
PHRX Average Weekly Movement	n/a
Healthcare Industry Average Movement	6.7%
Market Average Movement	6.4%
10% most volatile stocks in US Market	16.8%
10% least volatile stocks in US Market	3.0%

Stable Share Price: PHRX's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: Insufficient data to determine PHRX's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
n/a	n/a	n/a	n/a

Pharmagen, Inc. distributes specialty drugs to hospitals, acute care facilities, surgery centers, and other healthcare practitioners in the United States. The company sources and distributes specialty drugs, blood plasma derivatives, specialty products, vaccines, anti-infectives, and hard-to-find pharmaceuticals. It offers plasma derivatives for treating serious medical conditions, such as cancer, hemophilia, rheumatoid arthritis, multiple scleroses, blood disorders, hepatitis, and HIV; and specialty products for treating respiratory, oncology, cardiovascular, and hormonal syndromes.

Pharmagen, Inc. Fundamentals Summary

How do Pharmagen's earnings and revenue compare to its market cap?
PHRX fundamental statistics
Market cap	US$517.00
Earnings (TTM)	-US$6.43m
Revenue (TTM)	US$4.41m

0.0x

P/S Ratio

0.0x

P/E Ratio

Is PHRX overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
PHRX income statement (TTM)
Revenue	US$4.41m
Cost of Revenue	US$1.66m
Gross Profit	US$2.75m
Other Expenses	US$9.18m
Earnings	-US$6.43m

Last Reported Earnings

Mar 31, 2014

Next Earnings Date

n/a

Earnings per share (EPS)	0
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0.0%

How did PHRX perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/09/08 22:23
End of Day Share Price	2025/09/08 00:00
Earnings	2014/03/31
Annual Earnings	2013/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Pharmagen, Inc. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Paul Resnik	Merriman Capital, Inc